Olivier Dereure
Overview
Explore the profile of Olivier Dereure including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
194
Citations
1484
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
A New Case of Allergic Contact Dermatitis to Topical Simvastatin Used for Treatment of Porokeratosis
Raison-Peyron N, Girard C, Girod M, Dereure O
Contact Dermatitis
. 2025 Mar;
PMID: 40059073
No abstract available.
2.
Tedbirt B, Houivet E, Maho-Vaillant M, Golinski M, Calbo S, Prost-Squarcioni C, et al.
JAMA Dermatol
. 2025 Mar;
PMID: 40042819
No abstract available.
3.
Bozonnat A, Beylot-Barry M, Dereure O, DIncan M, Quereux G, Guenova E, et al.
EClinicalMedicine
. 2024 Dec;
79:102979.
PMID: 39720605
[This corrects the article DOI: 10.1016/j.eclinm.2024.102679.].
4.
Amiot M, Mortier L, Dalle S, Dereure O, Dalac S, Dutriaux C, et al.
EClinicalMedicine
. 2024 Dec;
78:102960.
PMID: 39717261
Background: Immune checkpoint inhibitors (ICIs) have demonstrated their efficacy with a 7.5-year overall survival (OS) close to 50% for advanced stages. The design of clinical trials provides for treatment until...
5.
Samaran Q, Dereure O, Raison-Peyron N
Contact Dermatitis
. 2024 Dec;
92(4):299-303.
PMID: 39704158
Background: 2-(Thiocyanomethylthio)benzothiazole (TCMTB) is a fungicide product widely used in the leather industry, particularly since the 1990s. However, reports of allergic contact dermatitis triggered by this chemical are scarce. Objectives:...
6.
Basset-Seguin N, Djermane M, Herms F, Dalac S, Dereure O, Beylot-Barry M, et al.
J Eur Acad Dermatol Venereol
. 2024 Dec;
PMID: 39676714
No abstract available.
7.
Le Brun I, Dalle S, Mortier L, Dereure O, Rat S, Dutriaux C, et al.
Cancer
. 2024 Dec;
131(1):e35679.
PMID: 39645590
Background: Nivolumab obtained approval in advanced melanoma (AM) with weight-adjusted dose (WAD) administration (3 mg/kg/2 weeks). In 2018, the dosage regimen was changed to flat dose (FD) administration (240 mg/2...
8.
Karine B, Mortier L, Dereure O, Dalac S, Montaudie H, Legoupil D, et al.
Br J Dermatol
. 2024 Nov;
PMID: 39605282
Background: The Checkmate 067 randomized controlled trial, published in 2015, demonstrated improved progression-free survival and numerically, although not statistically, superior overall survival for ipilimumab + nivolumab. The objective of this...
9.
Macaire C, Lefevre W, Dalac S, Montaudie H, Legoupil D, Dereure O, et al.
Melanoma Res
. 2024 Nov;
35(1):50-59.
PMID: 39527777
The link between palliative care and oncology must continue to develop, taking into account advances in treatment.Immune checkpoint inhibition (ICI) for metastatic melanoma is associated with different types of response,...
10.
Passeron T, Fontas E, Boye T, Richard M, Delaporte E, Dereure O
JID Innov
. 2024 Sep;
4(6):100307.
PMID: 39310808
Rationale: Experimental data support the role for C5a-C5aR1 axis activation in bullous pemphigoid. We assessed the efficacy and safety of avdoralimab, a specific anti-C5aR1 mAb, for treating bullous pemphigoid. Methods:...